NASDAQ
24.10.25 | 22:00
1,920 US-Dollar
+3,78 % +0,070
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Shattuck Labs stellt auf UEG-Kongress innovativen Ansatz zur IBD-Behandlung vor | 1 | Investing.com Deutsch | ||
| 02.10. | Shattuck Labs, Inc.: Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel | 2 | GlobeNewswire (USA) | ||
| 26.08. | Shattuck Labs closes $103 million private placement led by OrbiMed | 2 | Investing.com | ||
| 26.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 26.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 22.08. | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 2 | Investing.com | ||
| 21.08. | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 316 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
| 14.08. | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
| 14.08. | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com | ||
| 14.08. | Shattuck Labs GAAP EPS of -$0.24 in-line | 2 | Seeking Alpha | ||
| 14.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 113 | GlobeNewswire (Europe) | - Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 - - On track to dose first participant in... ► Artikel lesen | |
| 05.08. | Shattuck Labs stock soars after $103 million private placement | 4 | Investing.com | ||
| 05.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million | 5 | GlobeNewswire (USA) | ||
| 15.07. | Shattuck Labs: Aktionäre wählen Direktoren und bestätigen Wirtschaftsprüfer auf jährlicher Hauptversammlung | 1 | Investing.com Deutsch | ||
| 15.07. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.05. | Shattuck Labs GAAP EPS of -$0.27 beats by $0.01 | 1 | Seeking Alpha | ||
| 01.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,455 | +1,56 % | NurExone setzt neue Standards: Patente und Qualität als Fundament für den nächsten Schritt | ||
| ONCO-INNOVATIONS | 0,815 | +3,16 % | Onco-Innovations Limited: Onco-Innovations Announces Private Placement | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / October 14, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| PRECIGEN | 3,826 | +2,85 % | Precigen, Inc.: Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory ... | 15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months
Reduction in surgeries compared to year... ► Artikel lesen | |
| ALECTOR | 1,290 | -0,77 % | GSK und US-Partner Alector stellen Tests an Demenzmittel nach Studienflop ein | LONDON (dpa-AFX) - Der Pharmakonzern GSK hat einen Flop bei seinen Forschungsarbeiten an einem Demenzmittel erlitten. Wie das Unternehmen am Mittwoch zusammen mit seinem Partner Alector verkündete... ► Artikel lesen | |
| KORRO BIO | 38,090 | +1,71 % | Korro Bio, Inc.: Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 | CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based... ► Artikel lesen | |
| FRACTYL HEALTH | 1,375 | +0,73 % | Fractyl Health, Inc.: Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity | RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the... ► Artikel lesen | |
| ALX ONCOLOGY | 1,745 | -0,29 % | Alx Oncology stock jumps after presenting preclinical ADC data at conference | ||
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,070 (+3,78 %) liegt der Kurs bei 1,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.